CagriSema ObesityWeek data ‘very encouraging’

Danish pharma major Novo Nordisk (NOV: N) has presented new post-hoc analyses from the Phase III REDEFINE 1 trial evaluating CagriSema (cagrilintide/semaglutide), an investigational injectable combination treatment for overweight or obese adults, and effects on well-known cardiovascular (CV) risk factors, including hypertension and systemic inflammation.

The results from the post hoc analysis of REDEFINE 1, exploring the CV risk reduction potential of investigational CagriSema, were presented during the ongoing ObesityWeek event in Atlanta, Georgia, and simultaneously published in Hypertension.

A post hoc analysis of REDEFINE 1 demonstrated a 10.9 mmHg reduction in systolic blood pressure with investigational CagriSema (2.4 mg/2.4 mg), allowing 40% of people on blood pressure medications to reduce or stop their medication.